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Key Points
• Red blood cell, platelet,
and white cell antigens
can be typed accurately
with a single, unified,
DNA-based test.
• As this test will be
embedded in national
genotyping studies, full
blood cell typing data
will be available for mil-
lions of individuals.
Each year, blood transfusions savemillions of lives. However, under current blood-matching
practices, sensitization to non–self-antigens is an unavoidable adverse side effect of
transfusion. We describe a universal donor typing platform that could be adopted by blood
services worldwide to facilitate a universal extended blood-matching policy and reduce
sensitization rates. This DNA-based test is capable of simultaneously typing most clinically
relevant red blood cell (RBC), human platelet (HPA), and human leukocyte (HLA) antigens.
Validation was performed, using samples from 7927 European, 27 South Asian, 21 East
Asian, and 9 African blood donors enrolled in 2 national biobanks. We illustrated the
usefulness of the platform by analyzing antibody data from patients sensitized withmultiple
RBC alloantibodies. Genotyping results demonstrated concordance of 99.91%, 99.97%, and
99.03% with RBC, HPA, and HLA clinically validated typing results in 89 371, 3016, and 9289
comparisons, respectively. Genotyping increased the total number of antigen typing results
available from 110980 to .1200 000. Dense donor typing allowed identification of 2 to
6 times more compatible donors to serve 3146 patients with multiple RBC alloantibodies,
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providing at least 1 match for 176 individuals for whom previously no blood could be found
among the same donors. This genotyping technology is already being used to type thousands
of donors taking part in national genotyping studies. Extraction of dense antigen-typing data
from these cohorts provides blood supply organizations with the opportunity to implement
a policy of genomics-based precision matching of blood.
Introduction
The European Blood Alliance collects 31 million units of blood
each year to provide life-saving support to an estimated 15 million
individuals with a wide range of medical conditions.1 It is common
practice to match red blood cells (RBCs) only for the ABO and RhD
groups to ensure transfusion safety and prevent the majority of fatal
hemolytic transfusion reactions (HTRs). However, sensitization to
non–self RBC antigens remains an unavoidable consequence of
this matching strategy.2-4
Annually, an estimated 3% (0.5 million) of patients become
sensitized to RBC antigens after a single transfusion episode,
with 60% of patients who receive regular transfusions becoming
immunized.5-10 Sensitization confers a lifetime risk of HTRs, which
from 2013 through 2017 were responsible for 17% (32 of 185) and
6% (7 of 110) of transfusion-related deaths reported to the US
Food and Drug Administration and Serious Hazards of Transfusion
UK, respectively.11,12 Sensitization can render transfusion-dependent
patients nontransfusable and cause hemolytic disease in pregnancy,
which is potentially life threatening to the fetus. Notwithstanding
these serious side effects, the introduction of a more precise
matching policy is resisted because of perceived logistical
challenges and donor typing costs.13
Antibody-based tests are the current gold standard for RBC antigen
typing; however, reliable reagents and high-throughput techniques
are not available for all clinically relevant antigens. DNA-based tests
have been used to overcome these limitations, and a range of in-
house and commercial assays have been developed for donor
genotyping.14-16 Studies have shown that antigen-negative blood
can be supplied for 99.8% (5661/5672) of complex blood requests
by using 43066 donors genotyped for a limited number of RBC
antigens.17 Despite this evidence most global blood supply organ-
izations have not genotyped large numbers of their blood donors. The
main reasons for this lack of uptake are the cost of current assays, the
fact that no existing test can type all clinically relevant RBC antigens,
and the lack of an algorithm for automated interpretation of results.
Furthermore, existing tests do not include typing for other transfusion-
relevant antigens, such as human leukocyte and platelet antigens (HLAs
and HPAs), which are necessary for supporting cancer patients.18,19
A universal donor-typing platform must identify all clinically relevant
RBC antigens for blood transfusions and HLAs and HPAs for platelet
transfusions. The physical test must be combined with software for
automated data interpretation and formatting so that it is immediately
usable by blood supply organizations. Importantly, the platform must
be cost effective and scalable to millions of donors and patients.
In earlier studies, we used whole-genome sequencing (WGS) and
whole-exome sequencing for comprehensive RBC and HPA typing
of patients, but sequencing has remained too costly to apply to vast
numbers of blood donors.20,21 The Blood transfusion Genomics
Consortium was established to capitalize on array technology recently
applied in studies to genotype millions of individuals worldwide.22-25
In this report, we describe the validation of a high-throughput,
genome-wide test repurposed for extensive blood donor antigen
typing, which is available at a cost of ;$40 per sample, inclusive of
equipment, labor cost, and analysis.
Methods
Study design
This study involved several interrelated components (Figure 1).
First, we collated knowledge on 1602 known DNA sequence
determinants of blood cell antigens.26-28 In an attempt to include
genetic variants that may become important to antigen typing in
the future, we also collated 9180 coding variants in 48 genes
relevant to antigen expression (supplemental Table 1), all of which
had minor allele frequencies .0.02% in large-scale sequencing
data sets.29-32 Second, we fabricated an array containing this
donor typing content and genotyped a small sample to detect any
manufacturing or technical errors. Third, we integrated donor-
typing content into the larger UK BioBank array design. The
resulting Applied Biosystems UK Biobank version 2 Axiom Array
(UKBBv2 array) includes content for both genome-wide typing
and all currently known antigen-coding variants in RBC antigen-
and HPA-encoding genes (Figure 2). Finally, the UKBBv2 array
was tested on samples and data from thousands of blood donors
by assessment of concordance between genetically and clinically
determined antigen types. We also illustrated the advantages of
donor genotyping by using referral data from difficult-to-match
patients and a case report.
Blood donor samples
DNA samples were collected from 7984 blood donors in England and
TheNetherlands; 507 donors enrolled in theNational Institute for Health
Research (NIHR) BioResource were used as a “test set” to detect
technical errors in the array fabrication process or data-processing
software. The remaining 7477 samples, from blood donors in
England (n 5 4795) and The Netherlands (n 5 2682) who had
consented to participate in the COMPARE and DIS-III studies,
were used as a “trial set” to validate the UKBBv2 donor genotyping
array. Participant enrollment, ethics, sample processing, and DNA
extraction methodologies used by the NIHR BioResource, COM-
PARE, and DIS-III studies have been reported.33,34
Genotyping and genotype QC
Each DNA sample was genotyped by using the Axiom genotyping
platform at the Microarray Research Services Laboratory (Santa
Clara, CA), in accordance with Axiom Best Practice Workflows.35
Total DNA of 750 ng at 30 ng/mL was used from each sample.
Genotypes were called using the AxiomGT1 algorithm included
with Applied Biosystems Array Power Tools v2.10.2 software.36
Quality control (QC) metrics for each plate, sample and probe set
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were calculated automatically with the software. In brief, this involves
analyzing the fraction of AT probe sets for which fluorescence is 2
standard deviations outside QC probe set fluorescence and assessing
genotype call rates for each sample and variant. Probe sets failing the
recommended thresholds were not used for analysis. For variants with
more than 1 probe set remaining, a single best probe set was selected
by using Fisher’s linear discriminant for cluster resolution.
To ensure that novel blood-typing content did not interfere with
historical population-screening array content, we compared array-wide
measured allele frequencies for 4795 COMPARE European-ancestry
trial set donors to those measured in WGS data of 8511 European-
ancestry participants in the NIHR BioResource pilot phase of the
100000Genomes Project (supplemental Figure 1).32We also visually
inspected genotype call plots of all newly added antigen-typing probe
sets, per the original UKBB study methodology (supplemental
Figure 2).22 Data generated by any poorly performing probe sets
were not used for further analysis (supplemental Table 2).
DNA-based antigen typing
After QC was completed, genotype data were converted to Variant
Call Format v4.2, using a combination of in-house software and
BCFtools v1.3.1.37,38 Array-based RBC and HPA typing was then
performed with the previously published bloodTyper algorithm
modified for application to array data.39 HLA types were imputed
from the array data with the freely available Applied Biosystems HLA
Analysis v1.1 tool, by using the HLA*IMP:02 HLA type imputation
model and multipopulation reference panel.40,41
Clinical antigen typing
Antigen typing data for the 7984 donors were generated by using
clinically accredited tests as part of routine donor typing by National
Health Service Blood and Transplant (NHSBT) and Sanquin. Only
antigen types that had been verified by at least 2 independent
measurements were used. We refer to these antigen types as
“clinical types” as they are a combination of antibody- and DNA-
determined types. Results were available for 48 RBC, 11 HPA, and
6 HLA antigens (supplemental Table 3).
Clinical typing results for ABO, D, C, c, E, e, K, k, Kpa, Jka, Jkb, Fya,
Fyb, Lea, Leb, Lua, M, N, S, and s antigens were produced primarily
using commercial high-throughput serological phenotyping systems
(the Olympus PK7300 instrument, for example). Clinical types for
the other RBC antigens were produced using in-house manual
antibody-based typing tests. In-house polymerase chain reaction
(PCR)–based techniques were used to type antigens such as Doa,
Dob, and LAN, where no reliable antibody testing reagents are
available. HLA typing results were produced with commercially
available genotyping tests or in-house next-generation sequencing
tests. HPA genotyping was performed with in-house–developed
PCR-based tests.
RBC antigen and HPA typing concordance analysis
Antigens for which fewer than 10 comparisons between clinical and
array antigen types were possible were excluded from the concor-
dance analysis (supplemental Table 3). We also excluded the Lea and



































Figure 1. Overall project workflow. (A) Significant
stages of the project. (i) Variants underpinning antigen
expression and those in antigen-encoding genes in se-
quence variation databases were collected for in-
corporation into an array design. (ii) An array was
fabricated containing only donor-typing content, and the
small test set of donor samples was used to detect
manufacturing or technical errors. (iii) Based on the
results of the previous step, algorithmic changes were
made to improve variant and antigen calling and donor-
typing content was integrated into the UK Biobank Ax-
iom array design. (iv) The resulting UK Biobank version
2 array was fabricated and the large trial set of donor
samples was used to assess antigen typing perfor-
mance. (B) Typical array testing cycle.











 user on 17 February 2021
significant and the International Society of Blood Transfusion (ISBT)
table required for variant interpretation is lacking.26,27 P1 antigen
typing was disabled in bloodTyper, because themolecular basis of this
antigen was not defined at the time of platform design.42
HLA typing concordance analysis
Four-digit HLA types were imputed from UKBBv2 array data by using
the Applied Biosystems HLA Analysis v1.1 algorithm, which uses the
HLA type-imputation model, HLA*IMP:02, and a multipopulation
reference panel. Imputed HLA types were then compared with clinical
HLA typing data extracted from NHSBT and Sanquin databases, with
the following match algorithm:
1. Allele match: both results match for the first 2 fields (eg, HLA-
A*32:01 and HLA-A*32:01:01).
2. String match: the clinical typing result is an ambiguous string of
“potential” alleles that contains the genotype-inferred result (eg,
HLA-A*02:01 is within HLA-A*02:01/HLA-A*02:04/HLA-A*02:07/
HLA-A*02:09).
3. Group match: both results match in the first field, but because of
the lack of clinical typing data, a second field comparison cannot
be made (eg, HLA-A*24:02 and HLA-A*24).







































































































































































































Figure 2. Genetic variation in antigen-controlling genes compared with array content. Tracks (1 to 5) from outside to inside: (1) representations of HPA (blue)- and
RBC antigen (red)–encoding genes; box length equates to the number of amino acids in the protein. RBC and HPA system names are annotated next to gene labels; (2 and
3) coding variants included on the UK Biobank (UKBB) v2 (brown) and UKBB (dark blue) array, respectively; (4) all coding variants with consequences in the gnomAD
database (green); (5) antigen-encoding variants in the ISBT and IPD-HPA databases (red). Bar length for tracks 2 to 5 represents gnomAD alternate allele frequency.
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Targeted next-generation sequencing of
discrepant samples
A targeted capture-sequencing assay was developed to resolve
discordance between clinical and array antigen typing results. The
assay design included all consensus coding sequences and 59 and
39 untranslated regions present in Ensembl and RefSeq for all
relevant RBC antigen- and HPA-encoding genes. In addition,
1000 bp upstream of the transcript start sites were targeted. In
total, 1 094 363 bp were targeted.
Aliquots of original DNA samples were retrieved from research
biobanks, and 1 mg of each sample was fragmented with the E220
ultrasonicator (Covaris, Inc, Woburn, MA), to obtain average-sized
fragments of 150-bp. Samples were processed using the TruSeq
DNA LT Prep kit (Illumina Inc, San Diego, CA). Two DNA libraries
were captured at the same time with a single reaction of the
SeqCap BG capture array (Roche NimbleGen, Inc, Madison,
WI). Enrichment was tested by quantitative PCR, measuring
the abundance of 4 control target regions before and after
DNA capture. The libraries were quantified by using the library
quantification method (KAPA Biosystem, Ltd, Cape Town, South
Africa) and sequenced by the Cancer Research UK Cambridge
Institute Core Genomics facility in pools of 24 samples in 1 Illumina
HiSeq 2000 lane, by 150-bp paired-end sequencing. QC and
analysis of targeted sequencing data were performed with the
previously published bloodTyper exome-sequencing workflow21 and
visual review of sequencing alignments and variant calls by a panel of
experts.
Results
Genotyping in this study was performed with 2 arrays of sequential
design and 2 separate sets of donor samples. First, an array was
fabricated that contained only donor-typing content and was
evaluated by using 507 DNA samples from the test set for
detection of manufacturing or technical errors. Second, donor-
typing content was integrated into the UKBB array design,
producing the UKBBv2 array, which was assessed in the 7477
DNA samples from the trial set.
Test array performance and Rh antigen
typing algorithm
Concordance between clinical and array antigen-typing results for
the test set was 87.17% in 7315 comparisons across 19 RBC
antigens for which clinical typing was available (supplemental
Figure 3). This analysis identified antigens, predominantly those
of the Rh system, for which the quality of genotyping was
unacceptably poor. The discordance was present for 2 reasons:
first, the most common reason for the D-negative phenotype in
Europeans is deletion of the entire RHD gene, and the initial
version of the array did not detect the RHD copy number
accurately. Second, genotyping of Rh antigens is known to be
challenging because of high sequence homology between the
RHD and RHCE genes.26 We made changes to array content
and developed algorithms to overcome these difficulties
(Figure 3). First, we tiled the RHD gene with 114 probe sets
at loci with the lowest sequence homology to the RHCE gene.
These probes allowed us to accurately identify the RHD copy
number by using the standard CNVmix algorithm (Figure 3A-B).35
Second, we used the array-determined RHD copy number to
segregate samples in 3 groups to overcome the effect of signal
interference caused by cross-binding of RHCE probes to the
RHD gene (Figure 3A,C). The application of this algorithm
significantly increased concordance in the test set to 99.99%,
98.71%, and 99.61%, for the D, C/c, and E/e Rh group antigens,
respectively (Figure 3D).
Large-scale, blinded trial of the UKBBv2 array
QC of 7477 trial set samples identified 15 samples with imputed
vs declared sex mismatches and more than 5 antigen-typing
discordances. Further investigation revealed that these discrepancies
were caused by either erroneous handling of samples (n 5 4) or
incorrect data entry in the study database (n5 11). The data from the
former category were excluded from further analysis, and the latter
were retained in the study after error correction (supplemental
Table 4), leaving 7473 samples in the final trial set. Overall
concordance between clinical and UKBBv2 antigen typing was
99.82% in 103 326 comparisons across 28 RBC antigens, 10
HPAs, and 6 HLA loci for which clinical typing data were
available (Figure 4; supplemental Table 3).
All but 57 of the 7473 trial set donors enrolled in this study were of
European ancestry. Of the non-European individuals, 27, 21, and 9
were of South Asian, East Asian, and African ancestries, re-
spectively. Antigen-typing concordance for these 57 individuals
was 100% in 835 comparisons across the 28 RBCs and 10 HPAs
compared.
RBC antigen-typing performance
Concordance between RBC antigen-typing results was 99.91% in
89371 comparisons across 28 antigens (Figure 4A-B). We catego-
rized the 72 (0.08%) remaining results according to the reason for
discordance (Figure 4A,C; supplemental Table 5). Discordances
(n5 33; 45.8%) were explained by erroneous clinical typing results.
In 19 of these cases, variants encoding variant antigen expression were
detected by the array, examples include Del (RHD*11, NM_016124:
c.885T), Kmod (KEL*02M.01, NM_000420.2:c.1088G.A), and Fy
x
(FY*02W.01, NM_001122951.2:c.265C.T, and NM_001122951.2:
c.298G.A). For carriers of these alleles, the chances of false-negative
antibody-based typing results are greatly increased. A unit of blood that
is erroneously typed as negative for a given antigen may boost
antibody levels in a previously sensitized patient.43 The remaining
14 discordances in this category involved antigens for which
current typing reagents have been known to give incorrect results
(n 5 4) or for which sequencing analysis confirmed array genotyping
results (n 5 10).
Sixteen of the discordances remain unresolved (supplemental
Table 5). However, in 6 of these cases, previously unobserved
DNA variants, which were likely to underpin an antigen-negative
phenotype were discovered by using the targeted sequencing
platform designed for discordance resolution. The absence of
these newly identified variants from the ISBT reference tables
prevented their use in antigen phenotype inference. To determine
the effect of these 6 unique variants on antigen expression,
functional studies are required; therefore, we regard these cases
as unresolved. For the remaining 10, we were unable to resolve
the cause of the discordance because of the lack of samples for
further analysis.
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HLA typing
Most blood supply organizations maintain panels of HLA class I–
typed apheresis platelet donors to support patients who are
refractory to ABO-compatible platelet concentrates related
to HLA class I antibodies. Clinical HLA typing data were
available for 1221 of the 7473 trial set donors. Concordance
between typing results across 6 HLA class I and II loci, at
2-field resolution, was 99.03% in 9289 comparisons (Figure 5;
supplemental Table 6).
HPA typing
A portion of patients with HLA class I antibodies also form HPA
antibodies. For these patients, platelet concentrates lacking the
relevant class I HLAs and HPAs are required. We report 99.96%
RHCERHD
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CN2 (D +/+) 
Figure 3. Novel Rh antigen-typing workflow. (A) Diagrammatic representations of the RHD and RHCE genes, the binding positions of array probes are indicated in red.
The probes spanning RHD are used for RHD copy number assessment and for RHCE: for example, the probe for typing variant NM_020485.5:c.307C.T, which is used for
C/c typing. (B) Results obtained for 2682 Dutch donor samples binned by RHD median copy number/probe set intensity ratio (log2), demonstrating that clear resolution of
RHD copy number for each individual can be achieved by using the array. (C) Genotype call plot for the C/c antigen variant NM_020485.5:c.307C.T in the RHCE gene.
Samples are colored by array-determined RHD copy number to allow visualization of the intensity shift caused by cross-binding of RHCE probes to RHD. Segregating samples
in this way allows for accurate genotypes to be called. (D) Improvement in Rh(C/c) and Rh(E/e) antigen-typing concordance resulting from application of the novel genotyping
algorithm.
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concordance in 3017 comparisons across 10 antigens, with only
a single discordant result observed, for HPA-5a (Figure 4; supplemental
Tables 3 and 5).
Impact of an extensively genotyped donor panel
For 7473 trial-set donors 37 RBC antigens and 11 HPAs had at
least 1 clinical typing result available. These 48 antigens formed
a data set that was representative of extended donor typing
programs conducted on British and Dutch donors (Figure 6A-B).
In contrast to clinical typing data, genotype-inferred antigen typing
was almost complete, with only 458 (0.13%) of 354624 possible
results missing (Figure 6C-D). Genotyping yielded 3.8 times more
types (47.9 vs 12.6 results per donor) compared with current
practice. Genotyping also allowed us to type the donors for 185
additional antigens for which no clinical typing results were
available. In total, 1.2 million antigen types, on average 214.6
per donor, were produced by genotyping.
To investigate the potential benefits of densely genotyping donors
we used data from patient referrals to NHSBT over a 5-year period.
Filtering this data set for “complex cases,” defined as patients with
at least 3 RBC alloantibodies, produced a set of 3146 referrals with
1253 unique alloantibody combinations (Figure 7A; supplemental
Table 7). We observed an inverse relationship between the probability
of finding a compatible donor and the number of alloantibodies
identified in a patient (Figure 7B). Using the trial set of 7473
donors as a “virtual stock,” we report a 2.6-fold greater probability of
identifying ABO- and RhD-compatible donors who are negative for
the relevant combination of antigens needed to support patients with
1 of the 1253 alloantibody combinations, when using the genotype
data. This translated to an additional 176 patients for whom
a matched donor could be identified. When finding donors for
the most common alloantibody profiles, genotyping data were
equivalent to clinical typing data, but for the rare combinations,
genotyping increased the average number of identified donors by
72 (Figure 7C). We were even able to identify a compatible donor
for a patient with alloantibodies against 9 different RBC antigens.
Immediate clinical benefit of extended typing data
Illustrating the clinical need for denser typing of donors, we present
a female patient with myelodysplastic syndrome with anti-E, -Coa,
and -Wra antibodies. Because of her bone marrow failure, she
required regular transfusions; however, no suitable donors were
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Figure 4. Concordance between clinical and UKBBv2 array antigen typing. (A) Overview of concordance analysis and high-level categorization of results. (B) Concor-
dance per antigen is shown as a percentage of the total number of comparisons (given at the top of each bar) with concordant and discordant results in green and red,
respectively. (C) Categorization by error type of discordances for the different RBC antigen systems and for the HPA-5 system.











 user on 17 February 2021
Querying genotyping results from the 2682 Dutch donors in this
study identified 5 compatible active donors; their donations have
now been used to provide life-saving transfusion support for this
patient.
Donor and patient health information
Because of the large number of genetic variants typed by the
UKBBv2 array, the utility of this platform extends far beyond antigen
typing for extended matching. For example, homozygosity for the
variant NM_000410.3:c.845G.A in the HFE gene is the most
common cause of hereditary hemochromatosis. A recent study
showed that 21.7% of male and 9.9% of female UKBB participants
with this genotype presented with iron-overload pathologies.44
Using the UKBBv2 array data, we identified 78 (1%) donors in the
trial set testing as homozygous for this variant. This information
provides blood supply organizations with an opportunity to reduce
the risk of such pathologies developing in these individuals by
recommending frequent donations.
Discussion
To ensure transfusion safety, blood is routinely matched for
ABO and RhD compatibility. However, this policy is not generally
applied to other RBC antigens, and each year;0.5 million patients
become sensitized as a consequence. These patients subsequently
require extended matching of blood to prevent HTRs, which are
occasionally lethal. This situation can become particularly pre-
carious in transfusion-dependent patients, and it has been shown
that extended matching from the beginning of transfusion support
brings immediate benefits by reducing the incidence of alloantibody
formation.45,46 To reduce the frequency of this serious hazard of
transfusion, some blood supply organizations have introduced an
extendedmatching policy for these patient groups. However, the cost
of implementing generalized extended-matching policies will not be
justified without conclusive evidence from randomized trials of
consequent reductions in morbidity or mortality. For such trials to
be possible, a comprehensive and affordable extended antigen-
typing assay is needed, to test large numbers of donors and
patients.
Herein, we report a technology that is already used to genotype
millions of individuals and is now optimized for donor typing. We
showed by genotyping 7473 donors, 99.92% concordance between
clinical and array antigen typing results in 103326 comparisons
across 44 clinically relevant RBC antigens and HLAs and HPAs. We
observed 1 HPA and 72 RBC discordances between clinical and
genetically inferred antigen type (0.08% of comparisons).
Thirty-four discordances were caused by incorrect clinical typing
results. In 22 of these cases, antigens were typed negative by
antibody-based clinical typing, but were correctly inferred to be
present by genotyping. Transfusion of such blood into patients who
have been presensitized with the corresponding antibody is clinically
unacceptable, as it may cause an HTR. For these cases, our data
showed that genotyping was superior to clinical typing. Importantly,
the array identified 2 individuals positive for the D antigen who were
erroneously typed serologically as D-negative. Further analysis of
genotyping and sequencing results revealed that these individuals
possessed the Del phenotype (RHD*11 and RHD*01EL.09).
Detection of variant Rh antigens such as Del is of particular importance
when providing blood for transfusion-dependent patients. Although the
array contains content to enable typing of all ISBT known Rh variant
antigens, further validation using a larger number of donors typed for
these antigens is needed.
Twenty-three discordant results were caused by an array genotype
error (n5 18) or incorrect bloodTyper interpretation (n5 5). Although
only 3 of these cases resulted in false-negative typing results, this error
type may result in an incompatible transfusion if blood units are issued
according to electronic cross-matching, using genotyping data alone.
After these observations, we made modifications to the bloodTyper
algorithm to reduce the chance that such errors would occur.
However, 7 discordances involved ABO antigens. Because of the
clinical severity of ABO- and RhD-mismatched blood, it remains
international best practice, to type every donation for these antigens
by using antibody-based methods.
The question of whether extended typing of blood donors improves
the efficiency of matching blood units to patients with multiple RBC
alloantibodies has been much debated. When extended genotyping
data were made available, we observed a 2.6-fold increase in the
number of donors identified to support 3146 complex patients with
multiple alloantibodies. The immediate clinical benefit of having
densely typed donors was demonstrated by a female patient with
severe anemia related to bone marrow failure who required blood
with an antigen-typing profile possessed by 1 in 200 donors.
Notwithstanding the relatively high frequency, no suitable donors
were present in The Netherlands, because donors are not routinely
typed for Coa and Wra, because reliable or affordable typing
reagents are lacking. Five compatible Dutch donors were identified
in the trial set of this study.
We did not alter the UKBB array content at the HLA locus, because

































Discordant Group match String match Allele match
Figure 5. Concordance between clinical and UKBBv2 array HLA-typing
results. Concordance per antigen is shown as a percentage of the total number of
comparisons (given at the top of each bar) with concordant and discordant results
in green and red, respectively. The concordance was assessed at group, string, and
allele levels.
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imputed with good accuracy from the original UKBB array data.40
However the level of accuracy has never been empirically verified by
direct comparison of array vs clinical grade HLA-typing data. We
provide this comparison, which showed excellent concordance at
a 99.03% accuracy at 2-field resolution. Typing at this resolution has
immediate value for the provision of HLA class I–matched platelet
concentrates for refractory patients and shows that the platform, if
widely applied, could be used to improve the composition of platelet
apheresis panels via identification of donors homozygous for rare HLA
class I haplotypes.
We used the HFE locus to illustrate that the array data can also be
used to inform policies about donor health and confirm that;1% of
donors are homozygous for the hemochromatosis-causing HFE
variant. Based on this observation, an estimated 12 000 individual
donors in England and The Netherlands could donate more
frequently, thereby reducing their risk of developing ill health while
adding to blood stocks.
Reflecting the donor registries of The Netherlands and Britain, only
0.7% of donors available for this study were of non-European
ancestry. Because of the low frequency of Rh variant antigens in
Europeans and their high frequency in patients of African ancestry
with hemoglobinopathy, further validation must be performed before
this test can be used to clinically type these patients and the
required donors for variant antigens. However, the complete
concordance between 835 antigen-typing results for the 57 non-
European individuals and the identification of 2 erroneous serological
typing results caused by variant RhD expression reported herein
provides support for further studies using samples from donors and
patients recruited by ancestry and specific blood antigen types.
We present, for the first time, an affordable genotyping assay
capable of simultaneously typing all clinically relevant human RBC
group antigens, which has been trialed in thousands of blood
donors. The test is available in 2 formats: a genome-wide–typing
array that can be used in population-scale genotyping studies and
a donor-typing array containing only content relevant to antigen
typing that can be used where genome-wide typing is not an option.
As the study was embedded in the national blood services of
England and The Netherlands, we were able to take a first look at
how high-volume comprehensive donor typing can be used to
simplify provision of compatible blood for sensitized patients with
alloantibodies against multiple RBC antigen groups. Uniquely, the
data generated in this study are being used to provide life-saving
transfusion support for a young female patient for whom no
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Figure 6. Comparison of clinical and UKBBv2 array antigen–typing availability in the trial set of samples. The presence of color represents a typing result (positive
or negative), and the absence of color indicates lack of a typing result. Clinical and UKBBv2 array antigen typing data are shown for British (blue; A,C) and Dutch donors
(orange; B,D).
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the immediate improvements in health care that this technology has
to offer.
We also see opportunities for improvements in the medium term.
With many health care systems making preparations for the era of
precision medicine, an increasing number of countries are genotyp-
ing a proportion of their population. The assay developed in this study
is nested within the platform already used for population-genotyping
studies, such as the FinnGen Biobank, Million Veteran Program,
Taiwan Precision Medicine Initiative, UK Biobank, and the impending
UK 5 Million study. The genotyping in these studies will provide full
blood cell antigen types on millions of individuals, giving blood supply
organizations the opportunity to implement a policy of genomics-
based transfusion medicine.
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